Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL23R | Q5VWK5 | 15/20 | 0.58 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.56 |
| ▸ | NPY2R | P49146 | 3/20 | 0.55 |
| ▸ | GHSR | Q92847 | 3/20 | 0.55 |
| ▸ | GLP1R | P43220 | 1/20 | 0.55 |
| ▸ | GCGR | P47871 | 1/20 | 0.55 |
| ▸ | GIPR | P48546 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30592733 | 0.93 | GLP1R (0.55) | IL23RNPY2RGHSRGLP1RGCGR | |
| SCHEMBL30097937 | 0.89 | IL23R (0.63) | IL23RNPY2RGHSR | |
| SCHEMBL31092855 | 0.89 | IL23R (0.67) | IL23RNPY2RGHSRGLP1RGCGR | |
| SCHEMBL31146245 | 0.89 | ERAP2 (0.60) | IL23RNPBWR1NPY2RGHSRGLP1R | |
| SCHEMBL29883780 | 0.87 | NPBWR1 (0.62) | IL23RNPBWR1NPY2RGHSR | |
| SCHEMBL29461984 | 0.87 | NPBWR1 (0.62) | IL23RNPBWR1NPY2RGHSR | |
| SCHEMBL29540171 | 0.87 | IL23R (0.64) | IL23RNPBWR1GLP1RGCGRGIPR | |
| SCHEMBL31105428 | 0.86 | IL23R (0.71) | IL23R | |
| SCHEMBL11331814 | 0.86 | IL23R (0.67) | IL23R | |
| SCHEMBL11331799 | 0.86 | IL23R (0.67) | IL23R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250276116-A1 | METHODS OF MITIGATING MYOCARDIAL DAMAGE DUE TO EXTRACORPOREAL MEMBRANE OXYGENATION | TUFTS MEDICAL CENTER, INC. | 2025-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250276116-A1 | METHODS OF MITIGATING MYOCARDIAL DAMAGE DUE TO EXTRACORPOREAL MEMBRANE OXYGENATION | TNNI3, TNNT2, MB | IL23R 4785/4885NPBWR1 4341/4885NPY2R 4654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.